Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Patient and Survivor Care

Type: Poster Session

Time: Saturday June 3, 1:15 PM to 4:45 PM

Location: Hall A

Minocycline to reduce cancer pain in patients with multiple myeloma: A phase II randomized trial.

Sub-category:
Symptom Management/Supportive Care/Palliative Care

Category:
Patient and Survivor Care

Meeting:
2017 ASCO Annual Meeting

Abstract No:
10100

Poster Board Number:
Poster Session (Board #89)

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 10100)

Author(s): Xin Shelley Wang, Charles S. Cleeland, Qiuling Shi, Seema Prasad, Raza H Bokhari, Robert Orlowski; Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract Disclosures

Abstract:

Background: Patients with multiple myeloma (MM) experience substantial pain that may be from disease and/or post autologous stem cell transplant condition, and exacerbated by maintenance therapy. Minocycline is a readily available, low-cost antibiotic with anti-inflammatory properties. We conducted a phase II randomized, double-blinded, placebo controlled clinical trial to investigate the effect of minocycline in reducing patient-reported symptoms during maintenance therapy. Methods: Adults with MM scheduled for maintenance therapy at a single-institution were consented and randomized to receive either minocycline (100 mg twice daily) or placebo over the first 3 cycles maintenance therapy. Feasibility, toxicity, and patient-reported outcome data were prospectively collected. The MD Anderson Symptom Inventory-MM (0–10 scale) was used to assess pain and other symptoms weekly during 3 months trial. The longitudinal analysis for pain was compared between the minocycline and control groups to examine minocycline’s efficacy. Results: From April 2013 to Aug 2016, 88 patients were enrolled and 69 (78%) were evaluable: 33 were randomized to minocycline and 36 to placebo. There were no grade 3+ study medication-related adverse events. The worst 5 symptoms on MDASI-core during the trial were fatigue, pain, numbness/tinging, drowsiness, and disturbed sleep, followed by two MM module item bone aches and muscle weakness. Demographic and disease characteristics were not significantly different between groups. Longitudinal modelling of revealed a significant reduction on pain in minocycline group than placebo group (time and treatment group interaction, estimate=-0.068, P=.003). The favorite pain reduction in minocycline group vs placebo arm was represented by a moderate effect size (Cohen’s d =0.48). Conclusions: Minocycline during maintenance therapy for MM was feasible, had a low toxicity profile, and yielded a statistically significant positive signal on pain reduction. These preliminary results are encouraging and warrant a Phase III trial to test its efficacy. Clinical trial information: NCT01793051

 
Other Abstracts in this Sub-Category:

 

1. Managing cancer and living meaningfully (CALM): A randomized controlled trial of a psychological intervention for patients with advanced cancer.

Meeting: 2017 ASCO Annual Meeting Abstract No: LBA10001 First Author: Gary Rodin
Category: Patient and Survivor Care - Symptom Management/Supportive Care/Palliative Care

 

2. SCORAD III: Randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC).

Meeting: 2017 ASCO Annual Meeting Abstract No: LBA10004 First Author: Peter Hoskin
Category: Patient and Survivor Care - Symptom Management/Supportive Care/Palliative Care

 

3. Effect of inpatient palliative care during hematopoietic stem cell transplantation (HCT) hospitalization on psychological distress at six months post-HCT.

Meeting: 2017 ASCO Annual Meeting Abstract No: 10005 First Author: Areej El-Jawahri
Category: Patient and Survivor Care - Symptom Management/Supportive Care/Palliative Care

 

More...